Axplora Produced First Research Batches of Exatecan
The company aims to secure a European source for the topoisomerase I inhibitor used in drug conjugates.
Updated on Sept. 30, 2026 in Biotech
Live Poll
Do you believe efforts to diversify drug supply chains will improve access to new medicines?
Axplora has successfully produced the first R&D batches of Exatecan, marking the start of a project to establish a dedicated European supply chain. This development is currently at the research stage.
Why it matters
The move is designed to address a critical need for consistent quality, supply chain diversity, and predictable lead times for developers of antibody-drug conjugates (ADCs).
The production process utilizes an OEB 5 containment strategy at the Gropello Cairoli facility in Italy, designed to handle highly potent compounds. Axplora currently supports manufacturing for six FDA-approved antibody-drug conjugates.
The players
Axplora
A contract development and manufacturing organization specializing in complex small molecules and antibody-drug conjugate production with 35 years of high-potency synthesis experience.
The details
Exatecan is a topoisomerase I inhibitor—a class of drugs that disrupts DNA replication in cancer cells to prevent tumor growth. Axplora integrates its Farmabios manufacturing expertise in Italy with Novasep CDMO capabilities in France to link the synthesis of this payload with downstream linker and antibody-drug conjugate (ADC) assembly. This end-to-end process is intended to streamline the supply chain for complex biotherapeutics.
Timeline
Validation batches are targeted for completion by the end of 2026.
Registration activities are planned throughout 2027.
Initial GMP supply is targeted for release in late 2027.
The Tech Race
This project sits within a broader industry race to solve the supply chain bottlenecks currently complicating the rapid scaling of antibody-drug conjugates. By verticalizing the production of payload molecules like Exatecan, Axplora is competing to become a primary integrated partner for global drug developers.
This initiative primarily affects pharmaceutical and biotechnology developers who require high-potency payload manufacturing for clinical trials. Users can expect the transition to commercial-scale GMP supply to occur by late 2027.
The takeaway
The move represents a strategic effort to consolidate European-based capacity for specialized oncology payloads. Readers should watch for the validation batch results at the end of 2026 as a primary indicator of whether the facility can meet clinical scale requirements.
What happens next
Axplora has scheduled the completion of validation batches for the end of 2026, followed by formal registration activities in 2027.
Further reading
For more on the current state of drug manufacturing and supply chain infrastructure, visit Biotech.
Live Poll
Do you believe efforts to diversify drug supply chains will improve access to new medicines?
